Feed NTRA
NT

Natera

NTRA · NASDAQ

$370.64 -0.12% (-$0.44)
1M +13.10%
Market Cap $53.1B
P/E Ratio -
Div. Yield -
ROE 11.73%

Bulios Fair Price

$332.96

10.2% downside

Trenutna cena

$370.64

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica NTRA trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 19.61x
P/B 29.14x
P/FCF 740.36x
Growth
100 /100
Growing
Rev. growth 41.14%
Book val. growth 34.38%
EPS growth N/A
Profitability
27 /100
Weak
Gross margin 65.30%
Net margin 7.11%
FCF margin 2.65%
Quality
13 /100
Poor
ROIC 10.02%
ROE 11.73%
Asset turnover 1.02x
Debt
69 /100
Low
Debt/Equity 0.13x
Current ratio 3.00x
Int. coverage -24.51x
Stability
52 /100
Moderate
Beta 1.53x
Rev. volatility 13.31%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NTRA
Online

O podjetju

Natera, Inc. (NTRA) is an American biotechnology company specializing in the development and production of non-invasive genetic tests. With advanced technologies in reproductive medicine, oncology, and transplantation, Natera provides accurate and reliable tests for prenatal screening, detection of tumor markers, and transplant monitoring. The company is known for its focus on innovation and the use of advanced bioinformatics tools, enabling it to deliver high-quality genetic testing. Natera also collaborates with medical institutions and research organizations to enhance diagnostic capabilities. Natera, Inc. (NTRA) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetic testing and innovations in non-invasive diagnostics.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Steven Leonard Chapman

Employees

6,138

Headquarters

Austin

Prihajajoči dogodki

05 NOV.

Earnings

Upcoming earnings report

44d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.